# Optimization of IV Ketamine for Treatment Resistant Depression

> **NCT00768430** · PHASE2 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 73 (actual)

## Conditions studied

- Major Depressive Disorder (MDD)
- Treatment Resistant Depression (TRD)

## Interventions

- **DRUG:** Ketamine
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT00768430
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2012-09
- **Final completion:** 2012-11
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2014-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00768430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00768430, "Optimization of IV Ketamine for Treatment Resistant Depression". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00768430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*